Obi9 Technologies
Real-time biotech catalyst monitoring across filings, trials and regulators
Obi9 tracks more than 700 therapeutics companies across SEC filings, transcripts, press releases, trial registries, US and Chinese drug regulators and medical conferences, pushing AI-generated alerts to biotech investors. Delivery spans web, mobile, Slack, Teams, MCP and API.
GAII take
Sector specialisation is a sensible wedge; test alert latency and false-positive rate around clinical readouts and FDA decisions.
Sector specialisation is a sensible wedge; test alert latency and false-positive rate around clinical readouts and FDA decisions.
- Website
- obi9.ai
- Headquarters
- New York, NY, USA
- Company type
- Startup
- Status
- Active
- Founders
- Alessandro Chiavari
- Buyer
- Hedge fundsAsset managersVenture capital
- Asset class
- Public equities
- Workflow
- Research & diligenceRisk & monitoringIdea generation
- Ai capability
- Agents & automationNLP & sentimentSearch & RAG
- Delivery
- SaaS applicationAPI / data feed
GAII ID GAII-T0312 · Updated 2026-10-22 · Compiled from public sources for educational and informational purposes. Not investment advice.